Is Haleon plc (HLN) Overvalued?
We dive into why Haleon plc (HLN) could be considered overvalued on 2026-07-16, based on AAII’s Value Score and Grade.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc has a collaboration agreement with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global win as one strategy. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Commentary & Analysis
Is Haleon plc(HLN) Building Momentum?
With data as of June 25, 2025, we examine if Haleon plc(HLN) is consistently building momentum based on AAII's A+ Investor Momentum and Value Scores and Grades.Omar Beirat
Which Is a Better Investment, Corcept Therapeutics Incorporated or Haleon plc Stock?
Learn more about whether Corcept Therapeutics Incorporated or Haleon plc is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Which Is a Better Investment, Haleon plc or Jazz Pharmaceuticals plc Stock?
Learn more about whether Haleon plc or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Which Is a Better Investment, Haleon plc or Intra-Cellular Therapies, Inc. Stock?
Learn more about whether Haleon plc or Intra-Cellular Therapies, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Financial Summary
| Share Statistics | HLN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $43,131.9 | $618.0 | 92% |
|
| Shares Out (Mil) | 11,834.9 | 44.8 | 100% |
|
| Institutional Ownership | 99.9% | 85.3% | 96% |
|
| Float (Mil) | 8,778.9 | 47.4 | 99% |
|
| Beta | 0.25 | 0.70 | 15% |
|
| Avg Daily Volume (000s) | 6,460 | 390 | 94% |
|
| Price Change (52-week) |
1.3% | 68.6% | 46% |
|
| Growth | HLN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 1.9% | 6.7% | 23% |
|
| Net Income (5yr) | 7.5% | (1.6%) | 51% |
|
| EPS (5yr) | 8.1% | 14.9% | 43 |
|
| Dividends (5yr) | na | 0.0% | 56% |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | HLN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $14,796 | $291 | 88% |
|
| Net Income (TTM) (Mil) | $2,153 | ($11) | 92% |
|
| EPS (TTM) | $0.242 | ($0.700) | 48% |
|
| Operating Cash Flow (TTM) (Mil) | $3,517 | ($6) | 92% |
|
| Net Cash Flow (TTM) (Mil) | $251 | $5 | 86% |
|
| Long-Term Debt (Q1) (Mil) | $8,346 | $6 | 90% |
|
| Enterprise Value (Q1) (Mil) | $52,393 | $450 | 92% |
|
| Valuation | HLN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.03 | 2.78 | 72% |
|
| P/E | 41.1 | 17.4 | 80% |
|
| Dividend Yield | 1.3% | 0.0% | 70% |
|
| PEG (5yr hist) | 5.1 | 1.1 | 87% |
|
| Ratios | HLN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 65.6% | 67.0% | 77% |
|
| Net Margin | 14.6% | (2.3%) | 72% |
|
| ROA | 5.0% | (22.4%) | 72% |
|
| ROE | 9.9% | (20.2%) | 57% |
|
| Liabilities to Assets | 49.5% | 32.2% | 42% |
|
| F-Score | 8 | 3 | 93% |
|
Haleon plc did not pass any screens on 8/20/2026.
